ReNeuron Group Plc (LON:RENE) has published what it describes as very significant data highlighting the ability of its exosome therapy candidate to target specific organs of the body.
Exosome therapy is being explored by ReNeuron both as a potential new nanomedicine targeting cancer and as a delivery system for gene therapy treatments.
In a new poster presentation, ReNeuron researchers describe studies undertaken to investigate in vivo biodistribution of ExoPr0.
WATCH: ReNeuron's Michael Hunt on 'very significant' exosome therapy data
“The studies showed that ExoPr0 can be targeted to specific organs and tissues by either local or systemic administration. The uptake of ExoPr0 by particular cell types in target organs suggests that there also may be some specificity in uptake at the cellular level.”
Dr Randolph Corteling, head of research at ReNeuron, added: “The ability to target ExoPr0 to specific tissues and organs, including the brain, via clinically relevant routes of administration is highly significant.
“This, together with other recent positive data we have presented relating to the characterisation and scale-up potential of our exosome therapy candidates, clearly demonstrate the potential of this novel therapeutic platform to target multiple diseases."
The findings are being presented at the International Society for Extracellular Vesicles (ISEV) 2017 Annual Meeting in Toronto, Canada.